Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents https://doi.Org/10.1016/j.Jcin.2019.04.054.Patient death(s) were also included in the results of the journal article, however no causal link suggesting that the medtronic device(s) caused or contributed to the death(s) was provided.Information is provided in the future, a supplemental report will be issued.
|
This 3-arm clinical trial enrolled 3,514 all-comer patients who required percutaneous coronary intervention with drug eluting stents (des) implantation between (b)(6) 2012 and (b)(6) 2015.Of the 3,514 patients enrolled in this study, 1,173 patients were implanted with resolute integrity stents.938 patients had at least one complex lesion, 409 patients with at least one bifurcation lesion, 48 patients with at least one chronic total occlusion, 30 with at least one bypass graft, 81 with at least one ostial lesion and 265 with at least one severely calcified lesion.1,131 patients completed 3 year follow-up.The use of dual antiplatelet therapy (dapt) at 3 years was low (6.9%), as was the use of oral anti coagulation therapy plus antiplatelet agents (0.9%), without any between-des difference clinical outcomes included death, myocardial infarction, target vessel revascularization, target lesion revascularization, non¿target vessel revascularization and stent thrombosis.Despite substantial differences in stent backbone and polymer coating, all 3 des showed favorable 3-year safety and efficacy in all comers, without significant between-stent differences.
|